Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Merck
Johnson and Johnson
Medtronic
Boehringer Ingelheim

Last Updated: December 3, 2022

Details for Patent: 6,916,485


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 6,916,485 protect, and when does it expire?

Patent 6,916,485 protects ORAVIG and is included in one NDA.

This patent has twenty-four patent family members in fourteen countries.

Summary for Patent: 6,916,485
Title: Prolonged release bioadhesive therapeutic systems
Abstract:The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active dissolution test of more than 70% over 8 hours and to a method for its preparation. The bioadhesive therapeutic system may be in tablet form and may contain quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of the tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and may contain between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar.
Inventor(s): Aiache; Jean-Marc (Paris, FR), Costantini; Dominique (Paris, FR), Chaumont; Christine (Paris, FR)
Assignee: Bioalliance Pharma (Paris, FR)
Application Number:10/307,938
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Process; Use;

Drugs Protected by US Patent 6,916,485

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galt Pharms ORAVIG miconazole TABLET;BUCCAL 022404-001 Apr 16, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing Y TREATMENT OF OROPHARYNGEAL CANDIDIASIS See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,916,485

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France01 09811Jul 23, 2001

International Family Members for US Patent 6,916,485

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 373464 See Plans and Pricing
Austria 411003 See Plans and Pricing
Canada 2455633 See Plans and Pricing
China 101524337 See Plans and Pricing
China 1547464 See Plans and Pricing
Cyprus 1107828 See Plans and Pricing
Cyprus 1108796 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Express Scripts
Colorcon
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.